Partner Status (Abbreviated Descriptions of Strategic Alliances)

 

Genentech, Inc.– In March 1995, IDEC and Genentech entered into a collaborative agreement for the clinical development and commercialization of IDEC’s anti-CD20 monoclonal antibody, Rituxan® (Rituximab), for the treatment of B-cell (NHL). In November 1995, IDEC, Genentech and Zenyaku Kogyo Co. Ltd. entered into a joint development, supply and license agreement to which Zenyaku received exclusive rights to develop, market and sell Rituxan in Japan and IDEC will receive royalties on sales of Rituxan in Japan. In addition, IDEC and Genentech are co-promoting Rituxan in the United States. Genentech retained commercialization rights throughout the rest of the world, except in Japan. Genentech has granted F. Hoffmann-La Roche exclusive marketing rights outside the United States, and Roche has elected to market Rituxan under the trademark MabThera.

Schering AG– In June 1999, IDEC and Schering AG, Berlin, Germany, entered into a licensing agreement valued at approximately $47.5 million granting Schering AG exclusive marketing and distribution rights to IDEC’s investigational drug, ZEVALIN TM (Ibritumomab Tiuxetan), formerly known as IDEC-Y2B8. IDEC retains U.S. rights to ZEVALIN, which is a monoclonal antibody stably linked to the radioisotope yttrium-90. Under the terms of the agreement, Schering paid IDEC $13 million as an upfront licensing fee, and it will pay $15 million in committed funding for the development of ZEVALIN. Further, $19.5 million will be paid as milestone payments based on the achievement of certain development goals. In addition, Schering AG will pay IDEC an undisclosed royalty on eventual product sales outside of the United States.

Mitsubishi Chemical Corporation– In November 1993, IDEC entered into a three-year collaborative agreement and an ongoing license agreement with Mitsubishi for the development of a PRIMATIZED anti-B7.1 antibody. Under the terms of the agreement, IDEC may receive payments totaling $12.2 million to fund research of the PRIMATIZED anti-B7.1 antibody, subject to the attainment of certain milestones, of which $9.2 million has been recognized through December 31, 1998.

Seikagaku Corporation– In December 1994, IDEC and Seikagaku entered into a collaborative development agreement and a license agreement aimed at the development and commercialization of therapeutic products based on IDEC’s PRIMATIZED anti-CD23 antibodies. Under the terms of the agreement, Seikagaku may provide up to $26 million in milestone payments and support for research and development, subject to the attainment of certain milestones, of which $18.9 million has been recognized through December 31, 1998.

Eisai Co., Ltd.– In December 1995, IDEC and Eisai entered into a collaborative development agreement and a license agreement aimed at the development and commercialization of humanized and PRIMATIZED anti-gp39 antibodies. Under the terms of these agreements, Eisai may provide up to $37.5 million in milestone payments and support for research and development, subject to the attainment of certain milestones and satisfaction of other criteria, of which $29 million has been recognized through December 31, 1998.

Chugai Pharmaceutical Co., Ltd.– In March 1996, IDEC and Chugai entered into a worldwide license agreement for the company’s proprietary vector technology for high expression of recombinant proteins in mammalian cells. As part of the agreement, Chugai paid an upfront licensing fee of $4.5 million to the Company and will pay royalties on sales of Chugai products using the technology.

Boehringer Ingleheim GmbH– In December 1996, IDEC and Bl entered into a worldwide license agreement for the Company’s proprietary vector technology for high expression of recombinant proteins in mammalian cells. As part of the agreement, Bl paid an upfront licensing fee of $5.1 million to the Company and will pay royalties on sales of Bl products manufactured using the technology.

Kirin Brewery Co., Ltd. Pharmaceutical Division– In December 1997, IDEC and Kirin entered into a worldwide license agreement for the Company’s proprietary vector technology for high expression of recombinant proteins in mammalian cells. Kirin paid an upfront licensing fee of $6.3 million to the Company, which was recognized in the first quarter of 1998, and will pay royalties to the Company on sales of Kirin products manufactured using the technology.